Because they are effective in activating erythropoietin and regulating iron metabolism, roxadustat (FG-4592), daprodustat (GSK-1278863), vadadustat (AKB-6548), enarodustat (JTZ-951), molidustat (BAY 85–3,934) and desidustat (ZYAN1) are approved for the treatment of anemia in CKD. The gene discussed is EPO; the disease is chronic kidney disease.